Steve Aselage - Net Worth and Insider Trading
Steve Aselage Net Worth
The estimated net worth of Steve Aselage is at least $7 Million dollars as of 2024-04-23. Steve Aselage is the EVP, Chief Business Officer of Biomarin Pharmaceutical Inc and owns about 59,030 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $5 Million. Steve Aselage is the Director of Travere Therapeutics Inc and owns about 146,919 shares of Travere Therapeutics Inc (TVTX) stock worth over $864,618. Steve Aselage is also the Director of Acer Therapeutics Inc and owns about 483,741 shares of Acer Therapeutics Inc (ACER) stock worth over $319,317. Besides these, Steve Aselage also holds BioCryst Pharmaceuticals Inc (BCRX) . Details can be seen in Steve Aselage's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Steve Aselage has not made any transactions after 2022-11-29 and currently still holds the listed stock(s).
Transaction Summary of Steve Aselage
Steve Aselage Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Steve Aselage owns 5 companies in total, including BioCryst Pharmaceuticals Inc (BCRX) , Travere Therapeutics Inc (TVTX) , and Acer Therapeutics Inc (ACER) among others .
Click here to see the complete history of Steve Aselage’s form 4 insider trades.
Insider Ownership Summary of Steve Aselage
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
BCRX | BioCryst Pharmaceuticals Inc | 2019-11-18 | director |
TVTX | Travere Therapeutics Inc | 2022-05-11 | director |
ACER | Acer Therapeutics Inc | 2022-11-29 | director |
BMRN | Biomarin Pharmaceutical Inc | 2012-07-02 | SVP & Global Commercial Ops |
CTIC | CTI BioPharma Corp | 2004-02-02 | EVP & Global Commercial Ops |
Steve Aselage Latest Holdings Summary
Steve Aselage currently owns a total of 4 stocks. Among these stocks, Steve Aselage owns 59,030 shares of Biomarin Pharmaceutical Inc (BMRN) as of July 2, 2012, with a value of $5 Million and a weighting of 80.84%. Steve Aselage owns 146,919 shares of Travere Therapeutics Inc (TVTX) as of May 11, 2022, with a value of $864,618 and a weighting of 12.92%. Steve Aselage also owns 483,741 shares of Acer Therapeutics Inc (ACER) as of November 29, 2022, with a value of $319,317 and a weighting of 4.77%. The other 1 stocks BioCryst Pharmaceuticals Inc (BCRX) have a combined weighting of 1.48% among all his current holdings.
Latest Holdings of Steve Aselage
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
BMRN | Biomarin Pharmaceutical Inc | 2012-07-02 | 59,030 | 91.68 | 5,411,870 |
TVTX | Travere Therapeutics Inc | 2022-05-11 | 146,919 | 5.89 | 864,618 |
ACER | Acer Therapeutics Inc | 2022-11-29 | 483,741 | 0.66 | 319,317 |
BCRX | BioCryst Pharmaceuticals Inc | 2019-11-18 | 21,672 | 4.56 | 98,824 |
Holding Weightings of Steve Aselage
Steve Aselage Form 4 Trading Tracker
According to the SEC Form 4 filings, Steve Aselage has made a total of 0 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 95,345 shares on July 2, 2012, which brought Steve Aselage around $4 Million.
According to the SEC Form 4 filings, Steve Aselage has made a total of 19 transactions in Travere Therapeutics Inc (TVTX) over the past 5 years, including 0 buys and 19 sells. The most-recent trade in Travere Therapeutics Inc is the sale of 2,575 shares on May 11, 2022, which brought Steve Aselage around $56,444.
According to the SEC Form 4 filings, Steve Aselage has made a total of 4 transactions in Acer Therapeutics Inc (ACER) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Acer Therapeutics Inc is the acquisition of 409,836 shares on November 29, 2022, which cost Steve Aselage around $500,000.
More details on Steve Aselage's insider transactions can be found in the Insider Trading History of Steve Aselage table.Insider Trading History of Steve Aselage
- 1
Steve Aselage Trading Performance
GuruFocus tracks the stock performance after each of Steve Aselage's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Steve Aselage is 13.55%. GuruFocus also compares Steve Aselage's trading performance to market benchmark return within the same time period. The performance of stocks bought by Steve Aselage within 3 months outperforms 4 times out of 8 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Steve Aselage's insider trading performs compared to the benchmark.
Performance of Steve Aselage
Average Return
13.63%
Outperforming Transactions
50%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 30.12 | 13.55 | 17.06 | 13.63 | 32.76 | 8.19 |
Relative Return to S&P 500(%) | 28.16 | 12.01 | 12.96 | 8.03 | 15.6 | -2.8 |
Steve Aselage Ownership Network
Ownership Network List of Steve Aselage
Ownership Network Relation of Steve Aselage
Steve Aselage Owned Company Details
What does BioCryst Pharmaceuticals Inc do?
Who are the key executives at BioCryst Pharmaceuticals Inc?
Steve Aselage is the director of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include director & CEO Jon P Stonehouse , Vice President and CCO Charles K Gayer , and Exec Director & Finance - PAO Michael L Jones .
BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary
Over the past 18 months, Steve Aselage made no insider transaction in BioCryst Pharmaceuticals Inc (BCRX). Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net sale of 411,673 shares made by Jon P Stonehouse , a net sale of 10,125 shares made by Helen M. Thackray , and a net sale of 9,045 shares made by Michael L Jones .
In summary, during the past 3 months, insiders sold 0 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 495,199 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 495,199 shares.
BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
BioCryst Pharmaceuticals Inc Insider Transactions
Steve Aselage Mailing Address
Above is the net worth, insider trading, and ownership report for Steve Aselage. You might contact Steve Aselage via mailing address: 6300 Dumbarton Circle, Fremont Ca 94555.